Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 13/20 | 0.54 |
| ▸ | NPY1R | P25929 | 7/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121317 | 0.94 | TFPI (0.60) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31301806 | 0.89 | NPY4R (0.54) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30474555 | 0.88 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30350874 | 0.88 | TFPI (0.55) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30562995 | 0.88 | TFPI (0.55) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29591917 | 0.88 | NPY4R (0.54) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31013834 | 0.87 | NPY4R (0.57) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30111241 | 0.87 | OPRD1 (0.56) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30354440 | 0.87 | NPY4R (0.57) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30861237 | 0.87 | QRFPR (0.51) | TFPINPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | TFPI 169/4885NPY4R 4433/4885NPY1R 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.